Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Non-Hodgkin's Lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    « Previous 1  2  3  Next»
    Study title: Santana VM et al, MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma, Leukemia. 1993 Feb;7(2):187-91Santana VM et al, MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma, Leukemia. 1993 Feb;7(2):187-91
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 25103
    Study title: Santini G et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1998 Aug;16(8):2796-802Santini G et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1998 Aug;16(8):2796-802
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 25104
    Study title: Santini G et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1998 Aug;16(8):2796-802.Santini G et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1998 Aug;16(8):2796-802.
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 25105
    Study title: Meyer RM et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med. 1993 Dec 9;329(24):1770-6.Meyer RM et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med. 1993 Dec 9;329(24):1770-6.
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 25017
    Study title: Laver JH et al. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma. 2002 Jan;43(1):105-9Laver JH et al. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma. 2002 Jan;43(1):105-9
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 24981
    Study title: Link MP et al Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med. 1997 Oct 30;337(18):1259-66Link MP et al Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med. 1997 Oct 30;337(18):1259-66
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 24984
    Study title: Reiter A et al Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of theBerlin-Frankfurt-Münster Group J Clin Oncol. 1995 Feb;13(2):359-72Reiter A et al Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of theBerlin-Frankfurt-Münster Group J Clin Oncol. 1995 Feb;13(2):359-72
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 25082
    Study title: Reiter A et al. NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 2: An intermediate term analysis of the non-B-NHL therapy group. BFM Study group Klin Padiatr. 1994 Jul-Aug;206(4):234-41.Reiter A et al. NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 2: An intermediate term analysis of the non-B-NHL therapy group. BFM Study group Klin Padiatr. 1994 Jul-Aug;206(4):234-41.
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 25084
    Study title: de Andrea ML et al. A new treatment protocol for childhood non-Hodgkin's lymphoma: preliminaryevaluation. J Clin Oncol. 1990 Apr;8(4):666-71de Andrea ML et al. A new treatment protocol for childhood non-Hodgkin's lymphoma: preliminaryevaluation. J Clin Oncol. 1990 Apr;8(4):666-71
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 24843
    Study title: Jenkin-R-D, Anderson-J-R, Chilcote-R-R, Coccia-P, Exelby-P, Kersey-J, Kjeldsberg-C-R, Kushner-J, Meadows-A-T, Siegel-S, et al. The treatment of diffuse undifferentiated non-Hodgkin's lymphoma in children: the Childrens Cancer Study Group experience. IARC scientific publications, {IARC-Sci-Publ}, 1985, no. 60, p. 399-404, ISSN: 0300-5038.Jenkin-R-D, Anderson-J-R, Chilcote-R-R, Coccia-P, Exelby-P, Kersey-J, Kjeldsberg-C-R, Kushner-J, Meadows-A-T, Siegel-S, et al. The treatment of diffuse undifferentiated non-Hodgkin's lymphoma in children: the Childrens Cancer Study Group experience. IARC scientific publications, {IARC-Sci-Publ}, 1985, no. 60, p. 399-404, ISSN: 0300-5038.
    Active substance: PROCARBAZINE
    Study summary document link (including results):
    View full study record
    Document reference: 34753
    Study title: A Phase I study of gemcitabine in children with relapsed or refactory leukemia and non-Hodgkin's lymphoma
    Active substance: GEMCITABINE
    Study summary document link (including results):
    View full study record
    Document reference: 28882
    Study title: Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology - Patte C. et al - 2002 (J Clin Oncol. Jan 15;20(2):441-8)Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology - Patte C. et al - 2002 (J Clin Oncol. Jan 15;20(2):441-8)
    Active substance: LENOGRASTIM
    Study summary document link (including results):
    View full study record
    Document reference: 31039
    Study title: Sackmann-Muriel-F, Diez-B, Schvartzman-E, et-al. Oncology Department, Hospital de Ninos, 1425 Buenos Aires, Argentina. Comparison of two consecutive trials for treatment of childhood non-Hodgkin's lymphoma. Cancer {CANCER}, 1984, Vol/Iss/Pg. 54/12 (2863-2868).Sackmann-Muriel-F, Diez-B, Schvartzman-E, et-al. Oncology Department, Hospital de Ninos, 1425 Buenos Aires, Argentina. Comparison of two consecutive trials for treatment of childhood non-Hodgkin's lymphoma. Cancer {CANCER}, 1984, Vol/Iss/Pg. 54/12 (2863-2868).
    Active substance: PROCARBAZINE
    Study summary document link (including results):
    View full study record
    Document reference: 34821
    Study title: Aust N Z J Med. 1998 Feb;28(1):33-8. Erratum in: Aust N Z J Med 1998 Apr;28(2):197. Comparison of thallium-201 and gallium-67 scintigraphy in the evaluation of non-Hodgkin's lymphoma. Roach PJ, Cooper RA, Arthur CK, Ravich RB. Aust N Z J Med. 1998 Feb;28(1):33-8. Erratum in: Aust N Z J Med 1998 Apr;28(2):197. Comparison of thallium-201 and gallium-67 scintigraphy in the evaluation of non-Hodgkin's lymphoma. Roach PJ, Cooper RA, Arthur CK, Ravich RB.
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44524
    Study title: Patte C et al. Granulocyte colony-stimulating factor in induction treatment of children withnon-Hodgkin's lymphoma: a randomized study of the French Society of PediatricOncology. J Clin Oncol. 2002 Jan 15;20(2):441-8.Patte C et al. Granulocyte colony-stimulating factor in induction treatment of children withnon-Hodgkin's lymphoma: a randomized study of the French Society of PediatricOncology. J Clin Oncol. 2002 Jan 15;20(2):441-8.
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32207
    Study title: Anderson JR et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol. 1993 Jun;11(6):1024-32Anderson JR et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol. 1993 Jun;11(6):1024-32
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32221
    Study title: Reiter A et al. NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 2: An intermediate term analysis of the non-B-NHL therapy group. BFM Study group Klin Padiatr. 1994 Jul-Aug;206(4):234-41.Reiter A et al. NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 2: An intermediate term analysis of the non-B-NHL therapy group. BFM Study group Klin Padiatr. 1994 Jul-Aug;206(4):234-41.
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32219
    Study title: Santini G et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1998 Aug;16(8):2796-802.Santini G et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1998 Aug;16(8):2796-802.
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32214
    Study title: de Andrea ML et al. A new treatment protocol for childhood non-Hodgkin's lymphoma: preliminaryevaluation. J Clin Oncol. 1990 Apr;8(4):666-71de Andrea ML et al. A new treatment protocol for childhood non-Hodgkin's lymphoma: preliminaryevaluation. J Clin Oncol. 1990 Apr;8(4):666-71
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32229
    Study title: Tubergen DG et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J Clin Oncol. 1995 Jun;13(6):1368-76Tubergen DG et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J Clin Oncol. 1995 Jun;13(6):1368-76
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32215
    Study title: Santana VM et al, MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma, Leukemia. 1993 Feb;7(2):187-91Santana VM et al, MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma, Leukemia. 1993 Feb;7(2):187-91
    Active substance: BLEOMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 22797
    Study title: Olivieri A et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Ann Oncol. 2005 Dec;16(12):1941-8. Epub 2005 Sep 12Olivieri A et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Ann Oncol. 2005 Dec;16(12):1941-8. Epub 2005 Sep 12
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32201
    Study title: Economopoulos T et al. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP. Eur J Haematol. 2002 Mar;68(3):135-43.Economopoulos T et al. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP. Eur J Haematol. 2002 Mar;68(3):135-43.
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32204
    Study title: Kluin-Nelemans HC et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst. 2001 Jan 3;93(1):22-30.Kluin-Nelemans HC et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst. 2001 Jan 3;93(1):22-30.
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32210
    Study title: Laver JH et al. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma. 2002 Jan;43(1):105-9Laver JH et al. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma. 2002 Jan;43(1):105-9
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32205
    Study title: Link MP et al Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med. 1997 Oct 30;337(18):1259-66Link MP et al Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med. 1997 Oct 30;337(18):1259-66
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32213
    Study title: Gerhartz HH et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood. 1993 Oct 15;82(8):2329-39.Gerhartz HH et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood. 1993 Oct 15;82(8):2329-39.
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32220
    Study title: [Bone manifestations in non-Hodgkin's lymphoma in childhood and adolescence] German Rosenthal H, Kolb R, Gratz KF, Reiter A, Galanski M. Radiologe. 2000 Aug;40(8):737-44. German.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43476
    Study title: Intragumtornchai T et al. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma. Clin Lymphoma. 2000 Dec;1(3):219-25Intragumtornchai T et al. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma. Clin Lymphoma. 2000 Dec;1(3):219-25
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32209
    Study title: Meyer RM et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med. 1993 Dec 9;329(24):1770-6.Meyer RM et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med. 1993 Dec 9;329(24):1770-6.
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32216
    « Previous 1  2  3  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 14:54:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA